52North
PrivateLast Round
Grant
Dec 3, 2024
Total Funding Raised
$10.22M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
52North operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Grant round in December 2024.
52North is a medical technology company that develops in-vitro diagnostic and digital solutions to transform patient journeys in urgent care.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Defense Tech, Telemedicine
Business Model
B2B
Customer Profile
Hardware Sales, Subscription SaaS, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
52North Comparables
Compare 52North with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Entia | 91% | |
| Commure | 73% | |
| Soulbrain Holdings Co. Ltd | 69% |
For institutional investors. Book with your work email.
52North Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 3, 2024 | ||||
| Seed | Dec 3, 2024 | ||||
| Grant | Nov 22, 2022 | ||||
| Seed | Apr 29, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
52North Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Cancer Research Horizons | Seed |
| Cambridge Enterprise Ventures | Seed |
| Milltrust Ventures | Seed |
| OKG Capital | Seed |
| Meltwind Advisory | Seed |
| Cambridge Enterprise | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Open roles increased to 6, representing 23% of headcount.
- Jul 26, 2026
Monthly visitors increased 37% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 29, 2026
On Sep 29th '26, 52North received $4.24M in new funding in the United Kingdom, co-led by Macmillan Ventures and Hargreave Hale AIM VCT to support clinical validation, regulatory progress, and preparations to launch Neutrocheck(R).
For institutional investors. Book with your work email.
52North Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about 52North's valuation, stock price, and market status.
Is 52North a public or private company?
52North is a private company.
What is the current stock price of 52North?
52North is a private company, so its shares have no public market price. Caplight tracks 52North's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is 52North worth (valuation)?
Valuation information for 52North is not publicly available.
Can I buy 52North stock?
52North shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was 52North's last funding round?
52North's most recent funding round was Grant on December 3, 2024.
Who are the main investors in 52North?
Key investors in 52North include Cambridge Enterprise Ventures, Cambridge Enterprise, Meridian Health Ventures.
Will 52North IPO soon?
No public IPO plans have been announced for 52North.
How can I track 52North secondary market activity?
Caplight tracks bids, offers, and trades in 52North's shares on secondary markets.